Arcutis Biotherapeutics announces the JCAD published outcomes of ZORYVE

Arcutis Biotherapeutics announced that the Journal of Clinical and Aesthetic Dermatology, JCAD, published the outcomes of a comprehensive evaluation by an expert dermatologist panel assessing the formulation ingredients of ZORYVE topical foam, 0.3%. ZORYVE foam is a once-daily steroid-free treatment for seborrheic dermatitis. The published article supports the use of ZORYVE foam in all hair and skin types. “ZORYVE foam was formulated with the patient in mind, as a once-daily application and water-based formulation excluding fragrances and other known irritants. We are pleased to see such a strong endorsement from the expert dermatological panel, who bring their medical and cosmetic expertise from clinical practice and research, on the formulation qualities of ZORYVE foam that make it compatible with all hair and skin types for the treatment of seborrheic dermatitis,” said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis.